kynurenic acid has been researched along with Idiopathic Parkinson Disease in 12 studies
Kynurenic Acid: A broad-spectrum excitatory amino acid antagonist used as a research tool.
kynurenic acid : A quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by a hydroxy group at C-4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Boosting KYNA levels, through interference with the KP enzymes or through application of prodrugs/analogs with high bioavailability and potency, is a promising clinical approach." | 2.82 | Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword? ( Ostapiuk, A; Urbanska, EM, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (33.33) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Ostapiuk, A | 1 |
| Urbanska, EM | 1 |
| Fathi, M | 1 |
| Vakili, K | 1 |
| Yaghoobpoor, S | 1 |
| Tavasol, A | 1 |
| Jazi, K | 1 |
| Hajibeygi, R | 1 |
| Shool, S | 1 |
| Sodeifian, F | 1 |
| Klegeris, A | 1 |
| McElhinney, A | 1 |
| Tavirani, MR | 1 |
| Sayehmiri, F | 1 |
| Rákóczi, K | 1 |
| Klivényi, P | 2 |
| Vécsei, L | 2 |
| Tan, L | 2 |
| Yu, JT | 1 |
| Hartai, Z | 1 |
| Janaky, T | 1 |
| Penke, B | 1 |
| Dux, L | 1 |
| Bezard, E | 2 |
| Boraud, T | 2 |
| Bioulac, B | 2 |
| Gross, CE | 2 |
| Ossowska, K | 1 |
| Lorenc-Koci, E | 1 |
| Konieczny, J | 1 |
| Wolfarth, S | 1 |
| Ravikumar, A | 1 |
| Deepadevi, KV | 1 |
| Arun, P | 1 |
| Manojkumar, V | 1 |
| Kurup, PA | 1 |
| Stone, TW | 1 |
| Wu, HQ | 1 |
| Rassoulpour, A | 1 |
| Schwarcz, R | 1 |
| Beal, MF | 1 |
| Matson, WR | 1 |
| Storey, E | 1 |
| Milbury, P | 1 |
| Ryan, EA | 1 |
| Ogawa, T | 1 |
| Bird, ED | 1 |
5 reviews available for kynurenic acid and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Topics: Alzheimer Disease; Animals; Brain; Excitatory Amino Acid Antagonists; Humans; Huntington Disease; Ky | 2022 |
Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's disease, Parkinson's disease, and Huntington's disease: A systematic Review and meta-analysis.
Topics: 3-Hydroxyanthranilic Acid; Adenosine; Alzheimer Disease; Humans; Huntington Disease; Hydroxyindoleac | 2022 |
[Neuroprotection in Parkinson's disease and other neurodegenerative disorders: preclinical and clinical findings].
Topics: Animals; Creatine; Dopamine Agonists; Glatiramer Acetate; Humans; Indans; Kynurenic Acid; Micronutri | 2009 |
The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Topics: Aging; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Enzyme Inhibitors; Humans; Hunting | 2012 |
Kynurenic acid antagonists and kynurenine pathway inhibitors.
Topics: Brain Ischemia; Epilepsy; Excitatory Amino Acid Antagonists; Humans; Kynurenic Acid; Kynurenine; Neu | 2001 |
7 other studies available for kynurenic acid and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Kynurenine metabolism in plasma and in red blood cells in Parkinson's disease.
Topics: Adaptation, Physiological; Aged; Brain; Erythrocytes; Female; Humans; Kynurenic Acid; Kynurenine; Ma | 2005 |
Presymptomatic revelation of experimental parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Kyn | 1997 |
Compensatory effects of glutamatergic inputs to the substantia nigra pars compacta in experimental parkinsonism.
Topics: Animals; Disease Models, Animal; Glutamic Acid; Kynurenic Acid; Macaca; Parkinson Disease; Substanti | 1997 |
The role of striatal glutamate receptors in models of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dizocilpine Maleate; Electromyography; Excitatory | 1998 |
Tryptophan and tyrosine catabolic pattern in neuropsychiatric disorders.
Topics: Adult; Biogenic Monoamines; Brain Diseases; Brain Neoplasms; Digoxin; Epilepsy, Generalized; Erythro | 2000 |
Effect of systemic L-DOPA administration on extracellular kynurenate levels in the rat striatum.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Astrocytes; Dopamine; Dose-Response Relationship, | 2002 |
Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex.
Topics: Aged; Alzheimer Disease; Cerebral Cortex; Energy Metabolism; Free Radicals; Humans; Huntington Disea | 1992 |